Pulmonary arterial hypertension (PAH) has a multifactorial pathobiology. Vasoconstriction,
remodeling of the pulmonary vessel wall, and thrombosis contribute to increased pulmonary …

… Morrell has received research grants from the British Heart Foundation, Cambridge NIHR
Biomedical Research Center, and Novartis and has received honoraria for educational …

… Morrell has received research grant support from the British Heart Foundation, the
Cambridge NIHR Biomedical Research Center, and Novartis, and has received honoraria for …

Although plasma proteins have important roles in biological processes and are the direct
targets of many drugs, the genetic factors that control inter-individual variation in plasma …

Background Most patients with familial primary pulmonary hypertension have defects in the
gene for bone morphogenetic protein receptor II (BMPR2), a member of the transforming …

… Dr Morrell has received a research grant from Novartis. The other authors report no conflicts…
Correspondence to Professor NW Morrell, Department of Medicine, University of Cambridge …

Background— Mutations in the type II receptor for bone morphogenetic protein (BMPR-II), a
receptor member of the transforming growth factor-β (TGF-β) superfamily, underlie many …

Most patients with rare diseases do not receive a molecular diagnosis and the aetiological
variants and causative genes for more than half such disorders remain to be discovered 1 . …

Background This study investigated the effect of the phosphodiesterase 5 inhibitor sildenafil
on the pulmonary vascular response to hypoxia in humans and mice. Methods and Results …

Knowledge of the pathobiology of pulmonary hypertension (PH) continues to accelerate.
However, fundamental gaps remain in our understanding of the underlying pathological …